These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 23285069)

  • 41. [Evaluation of the effectiveness of antibacterial substances in treating an experimental form of bubonic plague in monkeys].
    Romanov VE; Evstigneev VI; Vasil'ev NT; Shabalin BA; Paramonov VE
    Antibiot Khimioter; 2001; 46(8):6-8. PubMed ID: 11871319
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Gentamicin and tetracyclines for the treatment of human plague: review of 75 cases in new Mexico, 1985-1999.
    Boulanger LL; Ettestad P; Fogarty JD; Dennis DT; Romig D; Mertz G
    Clin Infect Dis; 2004 Mar; 38(5):663-9. PubMed ID: 14986250
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Postexposure Administration of a Yersinia pestis Live Vaccine for Potentiation of Second-Line Antibiotic Treatment Against Pneumonic Plague.
    Zauberman A; Gur D; Levy Y; Aftalion M; Vagima Y; Tidhar A; Chitlaru T; Mamroud E
    J Infect Dis; 2019 Aug; 220(7):1147-1151. PubMed ID: 31095689
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of Gentamicin Concentration and Exposure Time on Intracellular
    VanCleave TT; Pulsifer AR; Connor MG; Warawa JM; Lawrenz MB
    Front Cell Infect Microbiol; 2017; 7():505. PubMed ID: 29312891
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bacterial filamentation of Yersinia pestis by beta-lactam antibiotics in experimentally infected mice.
    Davis KJ; Vogel P; Fritz DL; Steele KE; Pitt ML; Welkos SL; Friedlander AM; Byrne WR
    Arch Pathol Lab Med; 1997 Aug; 121(8):865-8. PubMed ID: 9278616
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Isepamycin in prophylaxis and treatment of experimental plague due to FI+ and FI- variants of plague microbe].
    Smorodinova IuV; Shcherbaniuk AI; Ryzhko IV; Moldavan IA
    Antibiot Khimioter; 2005; 50(8-9):23-6. PubMed ID: 17016907
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Rapid antimicrobial susceptibility testing and β-lactam-induced cell morphology changes of Gram-negative biological threat pathogens by optical screening.
    McLaughlin HP; Sue D
    BMC Microbiol; 2018 Dec; 18(1):218. PubMed ID: 30563467
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of resistance selection and mutant growth fitness on the relative efficacies of streptomycin and levofloxacin for plague therapy.
    Louie A; Deziel MR; Liu W; Drusano GL
    Antimicrob Agents Chemother; 2007 Aug; 51(8):2661-7. PubMed ID: 17517837
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In vitro antimicrobial susceptibilities of strains of Yersinia pestis.
    Smith MD; Vinh DX; Nguyen TT; Wain J; Thung D; White NJ
    Antimicrob Agents Chemother; 1995 Sep; 39(9):2153-4. PubMed ID: 8540736
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dynamics of Yersinia pestis and its antibody response in great gerbils (Rhombomys opimus) by subcutaneous infection.
    Zhang Y; Dai X; Wang X; Maituohuti A; Cui Y; Rehemu A; Wang Q; Meng W; Luo T; Guo R; Li B; Abudurexiti A; Song Y; Yang R; Cao H
    PLoS One; 2012; 7(10):e46820. PubMed ID: 23071647
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Early interaction of Yersinia pestis with APCs in the lung.
    Bosio CM; Goodyear AW; Dow SW
    J Immunol; 2005 Nov; 175(10):6750-6. PubMed ID: 16272331
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Deletion of Braun lipoprotein gene (lpp) and curing of plasmid pPCP1 dramatically alter the virulence of Yersinia pestis CO92 in a mouse model of pneumonic plague.
    Agar SL; Sha J; Baze WB; Erova TE; Foltz SM; Suarez G; Wang S; Chopra AK
    Microbiology (Reading); 2009 Oct; 155(Pt 10):3247-3259. PubMed ID: 19589835
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Increased effectiveness of etiotropic therapy of experimental plague in albino mice at the stage of generalized infection].
    Ryzhkova VV; Pavlovich NV; Makarovskaia LN; Zurabian VA; Bespalova IA; Goncharov EK; Bugaeva OK; Malsova NN
    Antibiot Khimioter; 1996 Feb; 41(2):35-9. PubMed ID: 8929117
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Yersinia pestis endowed with increased cytotoxicity is avirulent in a bubonic plague model and induces rapid protection against pneumonic plague.
    Zauberman A; Tidhar A; Levy Y; Bar-Haim E; Halperin G; Flashner Y; Cohen S; Shafferman A; Mamroud E
    PLoS One; 2009 Jun; 4(6):e5938. PubMed ID: 19529770
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antibiotic treatment of experimental endocarditis due to vancomycin- and ampicillin-resistant Enterococcus faecium.
    Whitman MS; Pitsakis PG; Zausner A; Livornese LL; Osborne AJ; Johnson CC; Levison ME
    Antimicrob Agents Chemother; 1993 Oct; 37(10):2069-73. PubMed ID: 8257125
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Deletion of the Braun lipoprotein-encoding gene and altering the function of lipopolysaccharide attenuate the plague bacterium.
    Sha J; Kirtley ML; van Lier CJ; Wang S; Erova TE; Kozlova EV; Cao A; Cong Y; Fitts EC; Rosenzweig JA; Chopra AK
    Infect Immun; 2013 Mar; 81(3):815-28. PubMed ID: 23275092
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Influenza virus infection augments susceptibility to respiratory Yersinia pestis exposure and impacts the efficacy of antiplague antibiotic treatments.
    Vagima Y; Gur D; Erez N; Achdout H; Aftalion M; Levy Y; Zauberman A; Tidhar A; Gutman H; Lazar S; Israely T; Paran N; Melamed S; Brosh-Nissimov T; Chitlaru T; Sagi I; Mamroud E
    Sci Rep; 2020 Nov; 10(1):19116. PubMed ID: 33154422
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Combined use of quinolones with other antibiotics in treatment of experimental plague infection].
    Shcherbaniuk AI; Kasatkina IV; Ryzhko IV
    Antibiot Khimioter; 1994 May; 39(5):38-40. PubMed ID: 7857159
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Human anti-plague monoclonal antibodies protect mice from Yersinia pestis in a bubonic plague model.
    Xiao X; Zhu Z; Dankmeyer JL; Wormald MM; Fast RL; Worsham PL; Cote CK; Amemiya K; Dimitrov DS
    PLoS One; 2010 Oct; 5(10):e13047. PubMed ID: 20976274
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Lack of levofloxacin and moxyfloxacin efficacy in experimental plague of albino mice infected with nalidixic acid resistant pathogen (Nal(r))].
    Ryzhko IV; Trishina AV; Verkina LM
    Antibiot Khimioter; 2010; 55(11-12):22-4. PubMed ID: 21574421
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.